Janux Therapeutics (JANX) Retained Earnings (2021 - 2026)
Janux Therapeutics (JANX) reported Retained Earnings of -$375.7 million for Q1 2026, down 43.8% year-over-year from -$668.5 million in Q1 2025, and down 8804.82% on a QoQ basis from $4.3 million in Q4 2025.
Janux Therapeutics (JANX) has 6 years of Retained Earnings data on file, last reported at -$375.7 million in Q1 2026.
- Quarterly Retained Earnings fell 43.8% year-over-year to -$375.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$375.7 million (down 43.8% YoY) and the FY2025 annual result came in at $4.3 million, up 99.54% from the prior year.
- Retained Earnings eased to -$375.7 million in Q1 2026 per JANX's latest filing, from $4.3 million in the prior quarter.
- Across five years, Retained Earnings topped out at $4.3 million in Q4 2025 and bottomed at -$375.7 million in Q1 2026.
- The 5-year median for Retained Earnings is -$157.0 million (2023), against an average of -$157.0 million.
- The widest annual swing landed in 2022, when Retained Earnings sank 393454.17%; it then surged 101.28% in 2024.
- Tracing JANX's Retained Earnings over 5 years: stood at -$1.5 million in 2022, then slumped by 10894.33% to -$168.8 million in 2023, then surged by 101.28% to $2.2 million in 2024, then jumped by 99.54% to $4.3 million in 2025, then sank by 8804.82% to -$375.7 million in 2026.
- Per Business Quant, the three latest JANX Retained Earnings figures stand at -$375.7 million (Q1 2026), $4.3 million (Q4 2025), and -$319.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Janux Therapeutics | 914.29 Mn | 914.29 Mn | - | -375.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -375.70 Mn |
| Dec 31, 2025 | 4.32 Mn |
| Sep 30, 2025 | -319.40 Mn |
| Jun 30, 2025 | -295.10 Mn |
| Mar 31, 2025 | -261.27 Mn |
| Dec 31, 2024 | 2.16 Mn |
| Sep 30, 2024 | -217.50 Mn |
| Jun 30, 2024 | -189.50 Mn |
| Mar 31, 2024 | -183.50 Mn |
| Dec 31, 2023 | -168.76 Mn |
| Sep 30, 2023 | -157.01 Mn |
| Jun 30, 2023 | -145.40 Mn |
| Mar 31, 2023 | -127.90 Mn |
| Dec 31, 2022 | -1.54 Mn |
| Sep 30, 2022 | -94.41 Mn |
| Jun 30, 2022 | -77.70 Mn |
| Mar 31, 2022 | -60.82 Mn |
| Dec 31, 2021 | -270,000.00 |
| Sep 30, 2021 | 24,000.00 |
| Jun 30, 2021 | -23.23 Mn |